Capricor Therapeutics Inc. (CAPR) 6.3800 $CAPR
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Capricor executes private placement of equity
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 12:38PM CST
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
GlobeNewswire - Wed Feb 04, 8:10AM CST
Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has signed definitive agreements for the sale of approximately $7.0 million of the Company's common stock to select investors at a price of $4.25 per share. The closing of the offering is expected to take place on or about February 9, 2015, subject to the satisfaction of customary closing conditions.
InsiderInsights.com Daily Round Up 1/23/15: OPK, SWN, AFAM, RGI
InsiderInsights - at Seeking Alpha - Sun Jan 25, 3:27AM CST
RH: 86.77 (-1.55), AFAM: 30.88 (+0.37), MRD: 18.66 (+0.23), PPR: 5.37 (+0.03), JPM: 59.67 (+0.10), OPK: 13.80 (-0.28), AGRX: 8.57 (-0.41), RDI: 12.03 (unch), RSPP: 28.48 (+1.29), GRPN: 7.97 (+0.51), SWN: 27.36 (+0.51), ACN: 89.79 (+0.70), MA: 87.14 (-0.38), URI: 92.98 (+1.41), CRM: 62.85 (+1.59)
InsiderInsights.com Daily Round Up 1/22/15: SWN, CBIN, OPK, RWC
InsiderInsights - at Seeking Alpha - Fri Jan 23, 8:53AM CST
AFAM: 30.88 (+0.37), SRE: 105.56 (-1.11), SHLD: 35.70 (+2.32), OWW: 11.68 (-0.04), DLPH: 78.70 (+0.64), K: 63.20 (-0.10), MDVN: 104.71 (+0.67), NOW: 77.55 (+1.60), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), ARR: 3.13 (unch), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), CBIN: 27.23 (+0.08), SWN: 27.36 (+0.51), PAYC: 32.37 (-0.71)
Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
GlobeNewswire - Wed Jan 21, 7:00AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar on Wednesday, January 21, 2015 at 3:00 p.m. ET/12:00 p.m. PT.
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
GlobeNewswire - Mon Jan 12, 11:32AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the first three patients have been treated in its DYNAMIC clinical trial. The trial is being conducted by Dr. Raj Makkar and his colleagues at Cedars-Sinai Heart Institute in Los Angeles. The Phase I DYNAMIC trial, also known as the "Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells" trial, will evaluate CDCs (CAP-1002) in patients with advanced heart failure. The Phase I trial is being funded in part through a grant of approximately $3 million from the National Institutes of Health (NIH).
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 6:45AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marbán will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray's clients during a fireside chat session in the Rutherford Room of the New York Palace Hotel, December 2, 2014, at 9:00 a.m. EST.
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
GlobeNewswire - Tue Nov 18, 7:41AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced yesterday at the American Heart Association's Annual Scientific Sessions 2014, the one-year results of the Phase I ALLSTAR (Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration) clinical trial, which indicate that intracoronary injection of allogeneic cardiosphere-derived stem cells (CAP-1002) to achieve myocardial regeneration in patients with left-ventricular dysfunction who have had an anterior myocardial infarction appears to be safe, with no deaths, no acute myocarditis and no major adverse cardiac events.
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
GlobeNewswire - Tue Nov 18, 6:45AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced positive data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor's Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute. The abstract was presented at the Late Breaking Basic Science Posters and Reception at the American Heart Association's Scientific Sessions 2014 on November 17, 2014.
Capricor Therapeutics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:13AM CST
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
GlobeNewswire - Wed Nov 12, 7:30AM CST
Announced Plans for Cenderitide Clinical Program and Clinical Program for Duchenne Muscular Dystrophy
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
GlobeNewswire - Fri Nov 07, 7:38AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the Company will hold a conference call to discuss the data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor's Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute. An abstract entitled "Heart-derived Cell Therapy for Duchenne Cardiomyopathy: Cardiosphere-derived Cells and their Exosomes Improve Function, Restore Mitochondrial Integrity and Reverse Degenerative Changes in the Hearts of Mdx Mice," will be presented at the Late Breaking Basic Science Posters and Reception at the American Heart Association's Scientific Sessions 2014.
Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
GlobeNewswire - Fri Oct 31, 7:00AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Company management will hold a conference call to discuss third quarter 2014 business highlights on Wednesday, November 12, 2014, at 4:30 p.m. ET.
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
GlobeNewswire - Tue Oct 14, 7:08AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has entered into an agreement to acquire patent rights from Medtronic, Inc. (NYSE:MDT) relating to the formulation and pump delivery of natriuretic peptides. Capricor recently announced that it plans to develop a clinical program using Cenderitide, a natriuretic peptide, for the treatment of post-acute heart failure.
MDT: 75.26 (+0.33)
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
GlobeNewswire - Thu Oct 09, 7:23AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for the treatment of post-acute heart failure using Insulet's drug delivery system based on the OmniPodinsulin management system.
PODD: 32.00 (-0.07)
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
GlobeNewswire - Mon Oct 06, 6:11AM CDT
Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program for Duchenne Muscular Dystrophy (DMD) using CAP-1002, Capricor's lead product candidate. CAP-1002 is an allogeneic, off-the-shelf, investigational cell therapy derived from donor heart tissue and is infused directly into a patient's coronary arteries during a catheterization procedure. CAP-1002 is currently in Phase II clinical testing for adults with ischemic heart disease.
Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
GlobeNewswire - Thu Sep 18, 7:27AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation by Dr. Raj R. Makker, M.D., of Cedars-Sinai Medical Center, at the Transcatheter Cardiovascular Therapeutics (TCT) conference at the Walter E. Washington Convention Center, Washington, DC on September 16, 2014.
Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
GlobeNewswire - Wed Aug 13, 9:19AM CDT
Reports Encouraging Results From Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License With Cedars-Sinai Medical Center for Exosomes IP Portfolio
NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST
VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Capricor executes private placement of equity
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 12:38PM CST
Capricor Therapeutics Announces $7 Million Private Placement of Common Stock
GlobeNewswire - Wed Feb 04, 8:10AM CST
Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has signed definitive agreements for the sale of approximately $7.0 million of the Company's common stock to select investors at a price of $4.25 per share. The closing of the offering is expected to take place on or about February 9, 2015, subject to the satisfaction of customary closing conditions.
InsiderInsights.com Daily Round Up 1/23/15: OPK, SWN, AFAM, RGI
InsiderInsights - at Seeking Alpha - Sun Jan 25, 3:27AM CST
RH: 86.77 (-1.55), AFAM: 30.88 (+0.37), MRD: 18.66 (+0.23), PPR: 5.37 (+0.03), JPM: 59.67 (+0.10), OPK: 13.80 (-0.28), AGRX: 8.57 (-0.41), RDI: 12.03 (unch), RSPP: 28.48 (+1.29), GRPN: 7.97 (+0.51), SWN: 27.36 (+0.51), ACN: 89.79 (+0.70), MA: 87.14 (-0.38), URI: 92.98 (+1.41), CRM: 62.85 (+1.59)
InsiderInsights.com Daily Round Up 1/22/15: SWN, CBIN, OPK, RWC
InsiderInsights - at Seeking Alpha - Fri Jan 23, 8:53AM CST
AFAM: 30.88 (+0.37), SRE: 105.56 (-1.11), SHLD: 35.70 (+2.32), OWW: 11.68 (-0.04), DLPH: 78.70 (+0.64), K: 63.20 (-0.10), MDVN: 104.71 (+0.67), NOW: 77.55 (+1.60), SNCR: 43.89 (+1.06), OPK: 13.80 (-0.28), ARR: 3.13 (unch), RWC: 5.82 (+0.06), CDNA: 6.30 (-0.14), CBIN: 27.23 (+0.08), SWN: 27.36 (+0.51), PAYC: 32.37 (-0.71)
Capricor Therapeutics and CureDuchenne to Host Webinar on January 21, 2015 at 3:00 p.m. ET
GlobeNewswire - Wed Jan 21, 7:00AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases and CureDuchenne, a national nonprofit organization dedicated to finding a cure for Duchenne muscular dystrophy, invite participants to join a webinar on Wednesday, January 21, 2015 at 3:00 p.m. ET/12:00 p.m. PT.
Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure
GlobeNewswire - Mon Jan 12, 11:32AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the first three patients have been treated in its DYNAMIC clinical trial. The trial is being conducted by Dr. Raj Makkar and his colleagues at Cedars-Sinai Heart Institute in Los Angeles. The Phase I DYNAMIC trial, also known as the "Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells" trial, will evaluate CDCs (CAP-1002) in patients with advanced heart failure. The Phase I trial is being funded in part through a grant of approximately $3 million from the National Institutes of Health (NIH).
Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray's 26th Annual Healthcare Conference
GlobeNewswire - Tue Dec 02, 6:45AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced today that CEO and President Linda Marbán will deliver an overview of Capricor Therapeutics, Inc., to Piper Jaffray's clients during a fireside chat session in the Rutherford Room of the New York Palace Hotel, December 2, 2014, at 9:00 a.m. EST.
Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results
GlobeNewswire - Tue Nov 18, 7:41AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, announced yesterday at the American Heart Association's Annual Scientific Sessions 2014, the one-year results of the Phase I ALLSTAR (Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration) clinical trial, which indicate that intracoronary injection of allogeneic cardiosphere-derived stem cells (CAP-1002) to achieve myocardial regeneration in patients with left-ventricular dysfunction who have had an anterior myocardial infarction appears to be safe, with no deaths, no acute myocarditis and no major adverse cardiac events.
Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy
GlobeNewswire - Tue Nov 18, 6:45AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced positive data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor's Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute. The abstract was presented at the Late Breaking Basic Science Posters and Reception at the American Heart Association's Scientific Sessions 2014 on November 17, 2014.
Capricor Therapeutics reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:13AM CST
Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights
GlobeNewswire - Wed Nov 12, 7:30AM CST
Announced Plans for Cenderitide Clinical Program and Clinical Program for Duchenne Muscular Dystrophy
Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET
GlobeNewswire - Fri Nov 07, 7:38AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that the Company will hold a conference call to discuss the data from the laboratory of Eduardo Marbán, M.D., Ph.D., Capricor's Scientific Advisory Board Chairman and the Director of the Cedars-Sinai Heart Institute. An abstract entitled "Heart-derived Cell Therapy for Duchenne Cardiomyopathy: Cardiosphere-derived Cells and their Exosomes Improve Function, Restore Mitochondrial Integrity and Reverse Degenerative Changes in the Hearts of Mdx Mice," will be presented at the Late Breaking Basic Science Posters and Reception at the American Heart Association's Scientific Sessions 2014.
Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET
GlobeNewswire - Fri Oct 31, 7:00AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that Company management will hold a conference call to discuss third quarter 2014 business highlights on Wednesday, November 12, 2014, at 4:30 p.m. ET.
Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.
GlobeNewswire - Tue Oct 14, 7:08AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it has entered into an agreement to acquire patent rights from Medtronic, Inc. (NYSE:MDT) relating to the formulation and pump delivery of natriuretic peptides. Capricor recently announced that it plans to develop a clinical program using Cenderitide, a natriuretic peptide, for the treatment of post-acute heart failure.
MDT: 75.26 (+0.33)
Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation
GlobeNewswire - Thu Oct 09, 7:23AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program using Cenderitide for the treatment of post-acute heart failure using Insulet's drug delivery system based on the OmniPodinsulin management system.
PODD: 32.00 (-0.07)
Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)
GlobeNewswire - Mon Oct 06, 6:11AM CDT
Capricor Therapeutics, Inc.(OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, today announced that it plans to develop a clinical program for Duchenne Muscular Dystrophy (DMD) using CAP-1002, Capricor's lead product candidate. CAP-1002 is an allogeneic, off-the-shelf, investigational cell therapy derived from donor heart tissue and is infused directly into a patient's coronary arteries during a catheterization procedure. CAP-1002 is currently in Phase II clinical testing for adults with ischemic heart disease.
Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014
GlobeNewswire - Thu Sep 18, 7:27AM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, presented an abstract entitled "ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results" with an oral presentation by Dr. Raj R. Makker, M.D., of Cedars-Sinai Medical Center, at the Transcatheter Cardiovascular Therapeutics (TCT) conference at the Walter E. Washington Convention Center, Washington, DC on September 16, 2014.
Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights
GlobeNewswire - Wed Aug 13, 9:19AM CDT
Reports Encouraging Results From Phase I of the ALLSTAR Clinical Trial and Signed Exclusive License With Cedars-Sinai Medical Center for Exosomes IP Portfolio
